MBX Biosciences, Inc.
MBX Nasdaq
SEC CIK 1776111
Follow MBX Biosciences
Weekly email: filings, results
Net income
−$62.4M
−188.7% vs same quarter last year
EPS, diluted
−$1.29
−104.8% vs same quarter last year
Operating cash flow
−$34.9M
−61.9% vs same quarter last year
Operating income
−$66.3M
−177.3% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$87M |
| FY24 | −$61.9M |
| FY23 | −$32.6M |
| FY22 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$81.9M |
| FY24 | −$55.6M |
| FY23 | −$32.1M |
| FY22 | - |